Screener
Kiniksa Pharmaceuticals International, plc KNSA Income Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $243.6M+55.4% | $214.27M+55.5% | $202.13M+65.0% | $180.86M+61.2% | $156.8M+44.3% | ||
| $23.57M+26.7% | $20.8M+16.4% | $20.95M+17.0% | $20.26M+0.7% | $18.6M+51.0% | ||
| $220.03M+59.2% | $193.47M+61.3% | $181.18M+73.1% | $160.6M+74.4% | $138.19M+43.5% | ||
| 90.3%+2.2pp | 90.3%+3.3pp | 89.6%+4.2pp | 88.8%+6.7pp | 88.1%-0.5pp | ||
| $40.9M+118% | $27.48M+42.2% | $34.61M-1.7% | $24.17M-7.3% | $18.75M-21.9% | ||
| $63.87M+36.3% | $61.15M+40.5% | $56.78M+40.1% | $49.1M+5.8% | $46.86M+10.5% | ||
| $27.19M+34.9% | $29.27M+121% | $19.77M+202% | $24.02M+349% | $20.16M+17,331% | ||
| 11.2%-1.7pp | 13.7%+4.0pp | 9.8%+25.5pp | 13.3%+21.9pp | 12.9%+13.0pp | ||
| $31.15M+36.1% | $32.68M+110% | $23.27M+237% | $27.16M+477% | $22.88M+893% | ||
| $5.71M+13.2% | $10.09M+43.6% | $9.07M— | $8.72M+58.8% | $5.05M-18.8% | ||
| $25.43M+42.6% | $22.59M+165% | $14.2M+260% | $18.44M+245% | $17.83M+556% | ||
| 10.4%-0.9pp | 10.5%+4.3pp | 7%+14.3pp | 10.2%+21.5pp | 11.4%+15.0pp | ||
| $0.30+30.4% | $0.27+145% | $0.18+250% | $0.23+228% | $0.23+483% | ||
| $27.67M+34.8% | $29.74M+118% | $20.24M+207% | $24.41M+364% | $20.52M+6,455% | ||
| 11.4%-1.7pp | 13.9%+4.0pp | 10%+25.4pp | 13.5%+21.7pp | 13.1%+12.8pp | ||
| $27.19M+34.9% | $29.27M+121% | $19.77M+202% | $24.02M+349% | $20.16M+17,331% |
FAQ
- What is Kiniksa Pharmaceuticals International, plc's revenue?
- Kiniksa Pharmaceuticals International, plc (KNSA) generated $840.8M in revenue over the trailing twelve months, up 58.9% year over year.
- Is Kiniksa Pharmaceuticals International, plc profitable?
- Kiniksa Pharmaceuticals International, plc reported $80.7M in net income over the trailing twelve months, a 9.6% net margin.
- What are Kiniksa Pharmaceuticals International, plc's profit margins?
- Gross margin is 89.8% and operating margin is 11.9%, with a 9.6% net margin.
- What is Kiniksa Pharmaceuticals International, plc's earnings per share?
- Kiniksa Pharmaceuticals International, plc's diluted EPS over the trailing twelve months is $0.98.
- Where does Kiniksa Pharmaceuticals International, plc's income statement data come from?
- Every line is extracted from Kiniksa Pharmaceuticals International, plc's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
